Advertisement
Singapore markets closed
  • Straits Times Index

    3,306.02
    +6.02 (+0.18%)
     
  • Nikkei

    38,596.47
    -36.55 (-0.09%)
     
  • Hang Seng

    18,028.52
    -306.80 (-1.67%)
     
  • FTSE 100

    8,237.72
    -34.74 (-0.42%)
     
  • Bitcoin USD

    64,432.41
    +150.20 (+0.23%)
     
  • CMC Crypto 200

    1,352.69
    -7.63 (-0.56%)
     
  • S&P 500

    5,464.62
    -8.55 (-0.16%)
     
  • Dow

    39,150.33
    +15.57 (+0.04%)
     
  • Nasdaq

    17,689.36
    -32.23 (-0.18%)
     
  • Gold

    2,334.70
    -34.30 (-1.45%)
     
  • Crude Oil

    80.59
    -0.70 (-0.86%)
     
  • 10-Yr Bond

    4.2570
    +0.0030 (+0.07%)
     
  • FTSE Bursa Malaysia

    1,590.37
    -2.32 (-0.15%)
     
  • Jakarta Composite Index

    6,879.98
    +60.66 (+0.89%)
     
  • PSE Index

    6,158.48
    -186.08 (-2.93%)
     

Nexstim Plc: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act

Nexstim Oyj
Nexstim Oyj

Company announcement, Helsinki, 11 June 2024 at 2 PM (EEST)

Nexstim Plc: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act

Nexstim Plc (NXTMH:HEX) (”Nexstim” or ”Company”) has received a notification pursuant to chapter 9, section 5 of the Securities Market Act from Kyösti Kakkonen on 10 June 2024.

The notification is based on the amendment to the Securities Market Act effective April 19, 2024, requiring shareholders to notify the target company and the Financial Supervisory Authority of their ownership and voting shares no later than two months after the enactment of this law if the shareholder's stake in the target company is at least five percent at the time the law takes effect and such share has not been previously disclosed.

 

% of shares and voting rights (total of 7.A)

% of shares and voting rights through financial instruments (total of 7.B)

Total of both in %
(7.A + 7.B)

Total number of shares and voting rights of issuer

Resulting situation on the date on which threshold was crossed or reached

8.28129

 

8.28129

6,764,562

Positions of previous notification (if applicable)

 

 

 

 

Notified details of the resulting situation on the date on which the threshold was crossed:

A: Shares and voting rights

Class/type of shares
ISIN code (if possible)

Number of shares and voting rights

% of shares and voting rights

 

Direct
(SMA 9:5)

Indirect
(SMA 9:6 ja 9:7)

Direct
(SMA 9:5)

Indirect
(SMA 9:6 ja 9:7)

FI4000506811

 

560,193

 

8.28129

SUBTOTAL A

560,193

8.28129

Information in relation to the person subject to the notification obligation:

Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:

Name

% of shares and voting rights

% of shares and voting rights through financial instruments

Total of shares, voting rights, and financial instruments

Kyösti Kakkonen

0

0

0

Kakkonen-Yhtiöt Oy

0

0

0

Joensuun Kauppa ja Kone Oy

6.41440

6.4144

433,906

K22 Finance Oy

1.866891

1.866891

126,287

Additional information: Kyösti Kakkonen holds 55.3 per cent of Kakkonen-Yhtiöt Oy, which holds 100 per cent of Joensuun Kauppa ja Kone Oy. Kyösti Kakkonen holds 77.7 per cent of K22 Finance Oy.

ADVERTISEMENT

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com

The Company’s Certified Advisor is Carnegie Investment Bank AB (publ).

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com

Attachment